Phase 1 clinical trial of CC-42344 as a treatment and prophylaxis for influenza A
Latest Information Update: 22 Aug 2024
At a glance
- Drugs CC 42344 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors Cocrystal Pharma Inc
Most Recent Events
- 14 Aug 2024 According to a Cocrystal Pharma media release, company Plans to initiate Phase 1 study in 2025
- 13 Aug 2023 According to a Cocrystal Pharma media release, company expect to begin this trial with inhaled CC 42344 in Australia in the first half of 2024.
- 19 May 2023 New trial record